

May 11, 2026
JCR Pharmaceuticals Co., Ltd.

Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2026

Hyogo, Japan – May 11, 2026 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ended March 31, 2026 disclosed on January 28, 2026 based on the current business performance.

1. Revision of consolidated financial forecasts for the fiscal year ended March 31, 2026

(Unit: Millions of yen)

	Net Sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share (yen)
Previously announced forecasts (A)	39,500	400	400	1,600	13.12
Revised forecasts (B)	40,300	500	1,100	2,100	17.87
Change (B-A)	800	100	700	500	—
Change (%)	2.0	25.0	175.0	31.3	—
Actual Results of the previous fiscal year	33,072	(6,650)	(7,477)	(4,759)	(38.43)

2. Reason for the revision

Net sales have been revised upward by ¥0.8 billion to ¥40.3 billion, as product sales are expected to remain firm.

Gross profit and selling, general and administrative expenses are expected to be largely in line with the previous forecast. Accordingly, operating profit has been revised upward by ¥0.1 billion.

Ordinary profit has been revised upward by ¥0.7 billion to ¥1.1 billion, reflecting the expected recognition of foreign exchange gains as non-operating income.

Profit attributable to owners of parent has been revised upward by ¥0.5 billion to ¥2.1 billion, mainly due to the expected increase in ordinary profit.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR’s global website: <https://jcrpharm.com/>

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###